关于报告

The pharmaceutical industry has made great strides in recent years developing novel medicines, however, in Latin America, access to most of the latest innovative medications is limited, particularly in oncology and rare disease. This report outlines a solution framework aimed at improving access to medicines within Latin America and increasing critical funding for innovative medicines. The solution framework builds upon real world examples from other countries that address inequality in access to innovative oncology and rare disease therapies. Possible solutions are presented for five countries (Brazil, Mexico, Argentina, Colombia, and Costa Rica) based on their unique context and needs.

报告摘要

拉丁美洲的医疗保健预算限lol买外围用什么软件制了，缺乏适当的创新药物融资框架，这带来了巨大的障碍，以获取和报销创新药物。在全球实施以克服资金挑战的14个解决方案中，有四种被评估为实施更可行，并且可能对拉丁美洲的医疗保健融资产生更大的影响。lol买外围用什么软件这四个政策建设者 - 通过公共/私人合作伙伴关系创建专门的药品资金，指定税收，社会影响债券和研发资本投资 - 可以构成在拉丁美洲资助创新药物的解决方案框架的基础。

Potential application of this framework in the context of multiple countries requires some adjustments to properly fit specific country contexts. Solutions put forth for Argentina, Colombia, Mexico, Costa Rica and Brazil do not include every component of the framework, but elements of the framework provide a basis for a tailored context-specific solution that can be further evaluated with government and other stakeholders. These country-level funding frameworks target current resources that could be reallocated to meet objectives of previously passed legislation on rare disease and oncology and involve innovative funds that can generate a sustainable and traceable funding mechanism to provide resources to clinicians and patients.